Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors

Ch'ng JLC, Polak JM, Bloom SR: Miscellaneous tumors of the pancreas.In The Exocrine Pancreas: Biology, Pathobiology and Diseases. VLW Go, JD Gardner, FP Brooks, E Lebenthal, EP DiMagno, GA Scheele (eds). New York, Raven Press, 1986, pp 763–771. Friesen SR: Tumors of the endocrine pancreas. N Engl J Med 306:580–590, 1982 Maton PN, Gardner JD, Jensen RT: The incidence and etiology of Cushing's syndrome in Zollinger-Ellison syndrome. N Engl J Med 315:1–5, 1986 Jensen RT, Doppman JL, Gardner JD: Gastrinoma.In The Exocrine Pancreas: Biology, Pathobiology and Diseases. VLW Go, JD Gardner, FP Brooks, E Lebenthal, EP DiMagno, GA Scheele (eds). New York, Raven Press, 1986, pp 727–744 Comi RJ, Gorden P, Doppman JL, Norton JL: Insulinoma.In The Exocrine Pancreas: Biology, Pathobiology and Diseases. VLW Go, JD Gardner, FP Brooks, E Lebenthal, EP DiMagno, GA Scheele (eds). New York, Raven Press, 1986, pp 745–761 Buchanan KD, Johnston CF, O'Hare MMT, Ardill JES, Shaw C, Collins JSA, Watson RGP, Atkinson AB, Hadden DR, Kennedy TL, Sloan JM: Neuroendocrine tumors: A European view. Am J Med 81(suppl 6B):14–22, 1986 Allison DJ: The nonsurgical management of metastatic endocrine tumours to the liver.In Interventional Radiology. RA Wilkins, M Viamonte (eds). Oxford, Blackwell Scientific Publications, 1982, pp 191–208 Boden G, Sivitz MC, Owen OE: Somatostatin suppresses secretin and pancreatic exocrine secretion. Science 190:163–165, 1975 Koerker DJ, Ruth W, Chideckel E: Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science 184:482–484, 1974 Bloom SR, Mortimer CH, Thorner MO, Hall R, Gomez-Pan A, Roy VM, Russel ACG, Coy DH, Kastin AJ, Schalley AV: Inhibition of gastrin and gastric acid secretion by growth hormone release inhibiting hormone. Lancet 2:1106–1109, 1974 Schlegel W, Rapits S, Harvey RF, Oliver JM, Pfeiffer EF: Inhibition of cholecystokinin-pancreozymin release by somatostatin. Lancet 2:166–167, 1977 Reichlin S: Somatostatin. N Engl J Med 309:1495–1501, 1556–1563, 1983 Long RG, Barnes AJ, Adrian TE, Mallinson CN, Brown MR, Vale W, Rivier JV, Christofides E, Bloom SR: Suppression of pancreatic endocrine tumour secretion of long-acting somatostatin analogue. Lancet 2:764–767, 1979 Lemon JR, Sircus W, Bloom SR, Mitchell SJ, Polak JM, Besser GM, Hall R, Coy DH, Kastin AJ, Schally AV: Investigation of a recurrent VIPoma. Gut 16:821–822, 1975 Ruskone A, Rene E, Chayvialle JA, Bonin N, Pignal F, Kremer M, Bonfils S, Rambaud JC: Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci 27:459–466, 1982 Adrian TE, Barnes AJ, Long RG, O'Shaughnessay DJ, Brown MR, Rivier J, Vale W, Blackburn AM, Bloom SR: The effect of somatostatin analogs on secretion of growth, pancreatic and gastrointestinal hormones in man. J Clin Endocrinol Metab 53:675–681, 1981 Curnow RT, Carey RM, Taylor A, Johanson A, Murad F: Somatostatin inhibition of insulin and gastrin hypersecretion in pancreatic islet-cell carcinoma. N Engl J Med 292:1385–1386, 1975 Christensen SE, Hansen AP, Lundbaek K, Orskov H, Seyer-Hansen K: Somatostatin and insulinoma. Lancet 1:1426, 1975 Berchtold P, Berger M, Wiegelmann W, Cuppers HJ, Gruneklee D, Reinwein D, Gries FA, Zimmerman H: Serum insulin suppression by somatostatin, diazoxide and phenytoin in insulinoma patients. 5th Int Cong Endocrinology, Hamburg, Abstract 229, 1976 Berger M, Bordi C, Cuppers HJ, Berchtold P, Gries FA, Munterfering H, Sailer R, Zimmerman H, Orci L: Functional and morphologic characterization of human insulinomas. Diabetes 32:921–931, 1983 Efendic S, Lins PE, Sigurdsson G, Ivemark B, Granberg PO, Luft R: Effect of somatostatin on basal and glucose-induced insulin release in five patients with hyperinsulinaemia. Acta Endocrinol (Copenhagen) 81:525–529, 1976 Lins PE, Efendic S: Responses of patients with insulinomas to stimulators and inhibitors of insulin release that have been linked with cyclic adenosine monophosphate. Diabetes 28:190–195, 1979 Fallucia F, Delle-Fave G, Giangrande L, Del Balzo P, De Magistris L, Carratu R: Effect of somatostatin on gastrin, insulin and glucagon secretion in two patients with Zollinger-Ellison syndrome. J Endocrinol Invest 4:451–453, 1981 Sohier J, Jeanmougin M, Lombrail P, Passa P: Rapid improvement of skin lesions in glucagonomas with intravenous somatostatin infusion. Lancet 1:40, 1980 Kahn C, Bhathena S, Recant L, Rivier J: Use of somatostatin and somatostatin analogs in a patient with a glucagonoma. J Clin Endocrinol Metab 53:543–549, 1981 Elsberg L, Glenthoj A: Effect of somatostatin in necrolytic migratory erythema of glucagonoma. Acta Med Scand 218:245–259, 1985 Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M: Metabolic clearance and plasma half-disappearance of exogenous somatostatin in man. J Clin Endocrinol Metab 48:50–53, 1979 Bloom SR, Polak JM: Glucagonomas, VIPomas, and somatostatinomas. J Clin Endocrinol Metab 9:285–297, 1980 Barnes AJ, Long RG, Adrian TE, Vale W, Brown MR, Rivier JE, Hanley J, Ghatei MA, Sarson DL, Bloom SR: Effect of a long-acting octapeptide analogue of somatostatin on growth hormone and pancreatic and gastrointestinal hormones in man. Clin Sci 61:653–656, 1981 Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher, TJ, Pless J: SMS 201-995: A very potent and selective octapeptide of somatostatin with prolonged actions. Life Sci 31:113–1140, 1982 Pless J, Bauer W, Briner U, Doepfner W, Marbach P, Maurer R, Petcher TJ, Reubi J-C, Vonderscher J: Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol 21(suppl 119):54–64, 1986 Kutz K, Nuesch E, Rosenthaler J: Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 21(suppl 119):65–72, 1986 Kraenzlin ME, Ch'ng JLC, Wood SM, Carr DH, Bloom SR: Long-term treatment of a vipoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastronenterology 88:185–187, 1985 Wood SM, Kraenzlin ME, Adrian TE, Bloom SR: Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue: Symptomatic and peptide responses. Gut 26:438–444, 1985 Anderson J, Bloom SR: Neuroendocrine tumours of the gut: Long-term therapy with the somatostatin analogue SMS 201-995. Scand J Gastroenterol 21(suppl 119):115–128, 1986 Ch'ng JL, Anderson JV, Williams SJ, Carr DH, Bloom SR: Remission of symptoms during long-term treatment of metastatic pancreatic endocrine tumours with long-acting somatostatin analogue. Br Med J 2:981–982, 1985 Maton PN, O'Dorisio TM, Howe BA, McArthur KE, Howard JM, Cherner JA, Malarky WB, Collen MJ, Gardner JD, Jensen RT: Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med 312:17–21, 1985 Maton PN, O'Dorisio TM, O'Dorisio MS, Malarkey WB, Gower WJ Jr, Gardner JD, Jensen RT: Successful therapy of pancreatic cholera with the long-acting somatostatin analogue SMS 201-995. Relation between plasma concentrations of drug and clinical and biochemical responses. Scand J Gastroenterol 21(suppl 119):181–186, 1986 Edwards C, Cann PA, Read NW, Holdsworth CD: Effect of two new antisecretory drugs on fluid and electrolyte transport in a patient with secretory diarrhoea. Gut 27:581–586, 1986 Edwards CA, Cann PA, Read NW, Holdsworth CD: The effect of somatostatin analogue SMS 201-995 on fluid and electrolyte transport in a patient with secretory diarrhoea. Scand J Gastroenterol 21(suppl 119):259–261, 1986 Santangelo WC, O'Dorisio TM, Kim JG, Severino G, Krejs GJ: Pancreatic cholera syndrome: Effect of a synthetic somatostatin analog on intestinal and water transport. Ann Intern Med 103:363–367, 1985 Santangelo WC, O'Dorisio TM, Kim JM, Severino G, Krejs GJ: VIPoma syndrome: Effect of a synthetic somatostatin analogue. Scand J Gastroenterol 21(suppl 119):187–190, 1986 Clements D, Elias E: Regression of metastatic VIPoma with somatostatin analogue SMS 201-995. Lancet 1:874–875, 1985 Clements D, Webb J, Heath D, McMaster P, Elias E: SMS 201-995 and endocrine tumours. Scand J Gastroenterol 21(suppl 119):252–255, 1986 Benson GD, O'Dorisio TM, Ellison EC, Woltering EA, Morrison AB: Control of watery diarrhoea syndrome in a patient with a vasoactive intestinal polypeptide-secreting tumor, using SMS 201-995 and dexamethasone. Scand J Gastroenterol 21(suppl 119):170–176, 1986 Brabant G, Muller MJ, Rotsch M, Havermann EK, Schmidt FW, Hesch RD: Treatment of carcinoid syndrome and VIPoma with a long-acting somatostatin analogue (SMS 201-995). Scand J Gastroenterol 21(suppl 119):177–180, 1986 Buchanan KD, Shaw C, O'Hare MMT, Dalzell G: Evaluation of SMS 201-995 in gastrointestinal APUDomas. Scand J Gastroenterol 21(suppl 119):199–205, 1986 Buchanan KD, Johnston CF, Shaw C, O'Hare MMT, Dalzell G, Brennan F, McKelvey STD: Somatostatin (SMS 201-995) therapy for gastrointestinal apudomas. Can J Physiol Pharmacol: Program of the 6th International Symposium on Gastrointestinal Hormones, Vancouver, Canada, July 6–10, 1986, p 64 Ellison EC, O'Dorisio TM, Benson GD: Modulation of functional gastrointestinal endocrine tumours by endogenous and exogenous somatostatin. Am J Surg 151:668–675, 1986 Lamberts SWJ: Non-pituitary actions of somatostatin. A review on the therapeutic role of SMS 201-995 (Sandostatin). Acta Endocrinol Suppl 276:41–55, 1986 Vinik A, Tsai S-T, Moattari AR, Cheung P, Echauser FE, Cho K: Somatostatin analogue (SMS 201-995) in the management of gastroentropancreatic tumors and diarrhea syndromes. Am J Med 81(suppl 6B):23–29, 1986 Sagman U, Sheldon F: Demonstration of tumor regression with somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. Can J Physiol Pharmacol: Program of the 6th International Symposium on Gastrointestinal Hormones, Vancouver, Canada, July 6–10, 1986 p 66 Koelz A, Kraenzlin M, Gyr K, Meiier V, Bloom SR, Heitz P, Stadler H: Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VI-Poma. Gastroenterology 92:527–531, 1987 Kvols LK, Buck M, Moertel CG, Schutt AJ, Rubin J, O'Connell MJ, Hahn RG: Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 107:162–168, 1987 Kane ME, O'Dorisio TM, Krejs GJ: Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide. N Engl J Med 309:1482–1485, 1983 Altimiri AF, Bhoopalam N, O'Dorisio TM, Lange CL, Sandberg L, Prinz RA: Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome. Surgery 100:989–996, 1986 Boden G, Ryan IG, Eisenschmid BL, Shelmet JJ, Owen OE: Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. N Engl J Med 314:1686–1689, 1986 Santangelo WC, Unger RH, Orci L, Dueno MI, Popma JJ, Krejs GJ: Somatostatin analogue-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration. Pancreas 1:464–469, 1986 Fiasse R, Ketelslegers JM, Pawels S, De Longueville M: Short-term effects of the long-acting somatostatin analogue SMS 201-995 in five cases of APUDoma (four with metastases) and in one case of systemic mastocytosis. Scand J Gastroenterol 21(suppl 119):212–216, 1986 Souquet J-C, Chayvialle J-A, Sassolas G, Partensky C: Biological and clinical efficacy of a long-acting somatostatin analogue (SMS 201-995) in secreting ADUDomas. Can J Physiol Pharmacol: Program of the 6th International Symposium on Gastrointestinal Hormones, Vancouver, Canada, July 6–10, 1986, p 64 Camisa C, O'Dorisio TM, Maceyko R, Mekhjian HS, Malarkey WB: Improvement of psoriasis with chronic use of somatostatin (SMS) analogue SMS 201-995. Clin Res 35:673A, 1987 O'Dorisio TM, Osei KW, Falko JM: Effects of somatostatin (SMS) analogue (201-995) on gastrin-releasing peptide (GRP) and pancreatic polypeptide (PP) during provocative testing in a benign insulinoma. Clin Res 33:877A, 1985 Osei KW, O'Dorisio TM: Malignant insulinoma: Effects of a somatostatin analog (compound SMS 201-995) on serum glucose growth, and gastroenteropancreatic hormones. Ann Intern Med 103:223–225, 1985 Osei K, Jackson RD, O'Dorisio T: Somatostatin analog SMS 201-995: Long-term effects on endogenous insulin secretion in a malignant insulinoma patient. Can J Physiol Pharmacol: Program of the 6th International Symposium on Gastrointestinal Hormones, Vancouver, Canada, July 6–10, 1986, p 68 Kaloustian E: Controle metabolique d'un insulinime par un agoniste d'action prolongee de la somatostatine. Presse Med 15:1882–1883, 1986 Lewis E, Tsai S, Vinik A: The role of long-acting somatostatin analogue (SMS 201-995) in the management of a patient with a benign insulin-secreting adenoma of the pancreas and a postoperative pancreatic fistula. Scand J Gastroenterol 21(suppl 119):217–222, 1986 Tsai S-T, Eckhauser MD, Thompson NW, Strodel WE, Vinik AI: Perioperative use of long-acting SMS 201-995 in patients with endocrine tumors of the gastroenteropancreatic axis. Surgery 100:778–785, 1986 Schrezenmeir J, Plewe G, Sturmer W, Kahaly G, Oppermann D, Krause U, del Pozo E, Kasper H, Beyer J: Treatment of APUDomas with the long-acting somatostatin analogue SMS 201-995. Investigations of therapeutic use and digestive side effects. Scand J Gastroenterol 21(suppl 119):223–227, 1986 Verschoor L, Uitterlinden P, Lamberts SWJ, del Pozo E: On the use of a new somatostatin analogue in the treatment of hypoglycemia in patients with insulinoma. Clin Endocrinol 25:555–560, 1986 Johnston DG, Davies RR, Turner SJ: Effects of somatostatin and SMS 201-995 on carbohydrate metabolism in normal man. Scand J Gastroenterol 21(suppl 119): 158–165, 1986 Worman B, Kutz K, Ottenjann R: Treatment of relapsing bleeding peptic ulcers with somatostatin analogue SMS 201-995 in a patient with Zollinger-Ellison syndrome. Hepatogastroenterology 32:1562–1563, 1985 Bofils S, Ruszniewski P, Costil V, Laucournet H, Vatier J, Rene E, Mignon M: Prolonged treatment of Zollinger-Ellison syndrome by long-acting somatostatin. Lancet 1:554–555, 1986 Bonfils S, Ruszniewski P, Laucournet H, Costil V, Rene W, Mignon M: Long-term management of Zollinger-Ellison syndrome with SMS 201-995, a long-lasting somatostatin analog. Can J Physiol Pharmacol: Program of the 6th International Symposium on Gastrointestinal Hormones, Vancouver, Canada, July 6–10, 1986, p 63 Ruszniewski P, Elouer-Blanc L, Mignon M, Bonfils S: Long-term treatment of Zollinger-Ellison syndrome (ZES) with long-acting somatostatin: Efficacy on gastric acid and gastrin secretions. Gastroenterology 92:1606, 1987 Ellison EC, O'Dorisio TM, Woltering EA, Sparks J, Mekhijian HB, Fromkes JJ, Carey LC: Efficacy of long-acting somatostatin analogue (SMS 201-995) in the ulcerogenic syndrome. Gastroenterology 88:1373, 1985 Ellison EC, O'Dorisio TM, Woltering EA, Sparks J, Mekhijian HB, Fromkes JJ, Carey LC: Suppression of gastrin and gastric acid secretion in the Zollinger-Ellison syndrome by long-acting somatostatin (SMS 201-995). Scand J Gastroenterol 21(suppl 119):206–211, 1986 Ellison EC, Gower WG, Elkhammas E, Woltering EA, O'Dorisio TM, Fabri PJ: Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue (SMS 201-995). Am J Med 81(suppl 6B):56–64, 1986 Ellison EC, O'Dorisio TM, Sparks J, Mekhijian HB, Fromkes JJ, Woltering EA, Carey LC: Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: Implications for the treatment of apudomas. Surgery 100:437–444, 1986 Geelhood GW, Bass BL, Mertz SL, Becker KL: Somatostatin analog: Effects of hypergastrinemia and hypercalcitoninemia. Surgery 100:962–970, 1986 Sacks H, O'Dorisio TM, Blackwell C, Tuttle S, Niell H, Mann J: Effects of somatostatin analogue 201-995 on hormone secretion and growth of a malignant gastrinoma in multiple endocrine neoplasia type-1. Program of the Endocrine Society 68th Annual Meeting, Anaheim, California, June 25–27, 1986, p 37 Shepherd JJ, Senator GB: Regression of liver metastases in patients with gastrin-secreting tumour treated with SMS 201-995. Lancet 2:574, 1986 Stockmann F, Richter G, Lembcke B, Conlon JM, Creutzfeld W: Long-term treatment of patients with endocrine gastrointestinal tumours with the somatostatin analogue SMS 201-995. Scand J Gastroenterol 21(suppl 119):230–237, 1986 Gyr KE, Whitehouse I, Beglinger C, Kohler E, Dettwiler S, Fried M: Human pharmacological effects of SMS 201-995 on gastric secretion. Scand J Gastroenterol 21(suppl 119):96–102, 1986 Norton JA, Doppman JL, Collen MJ, Harmon JW, Maton PN, Gardner JD, Jensen RT: Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Surgery 204:468–478, 1986 Cadiot G, Lehy T, Bonfils S, Lewin MJM: Long-acting somatostatin analog (SMS 201-995) partly antagonizes the trophic effect due to omperazole in rat gastric mucosa. Gastroenterology 92:1336, 1987 Von Werder K, Losa M, Muller OA, Schweiberer L, Fahlbusch R, del Pozo E: Treatment of metastasizing GRF-producing tumor with a long-acting somatostatin analogue. Lancet 2:282–283, 1984 Von Werder K, Losa M, Stalla GK, Muller OA, Mayr B, Schweiberer L, Fahlbusch LR: Long-term treatment of a metastasizing GRFoma with a somatostatin analogue (SMS 201-995) in a girl with gigantism. Scand J Gastroenterol 21(suppl 119):238–242, 1986 Ch'ng JLC, Christofides ND, Kraenzlin ME, Keshavarzian A, Burrin JM, Woolf IL, Hodgson HJF, Bloom SR: Growth hormone secretion dynamics in a patient with ectopic growth hormone-releasing factor production. Am J Med 79:135–138, 1985 Wilson DM, Hoffman AR: Reduction of pituitary size in a patient with a GRF secreting islet cell tumor by continuous infusion of a somatostatin analogue. Program of the Endocrine Society 6th Annual Meeting, Baltimore, Maryland, June 19–21, 1985, p 39 Wilson DM, Hoffman AR: Reduction of pituitary size by the somatostatin analogue SMS 201-995 in a patient with an islet cell tumour secreting growth hormone releasing factor. Acta Endocrinol 113:23–28, 1986 Lightman SL, Fox P, Dunne MJ: The effect of SMS 201-995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers. Scand J Gastroenterol 21(suppl 119):84–95, 1986 Wass JAH, Lytras N, Besser GM: Somatostatin octapeptide (SMS 201-995) in the medical treatment of acromegaly. Scand J Gastroenterol 21(suppl 119):136–140, 1986 Lamberts SWJ, Del Pozo E: Acute and long-term effects of SMS 201-995 in acromegaly. Scand J Gastroenterol 21(suppl 119):141–148, 1986 Tolis G, Malachtaris S, Mortoglou A, Rigas G, Saridakis C, Kamillaris T, Andreou J, Kimpouris Y, Del Pozo E, Yotis A: Therapy of acromegaly with SMS 201-995: Long-term studies: Scand J Gastroenterol 21(suppl 119):149–153, 1986 Rodding TW, Schally AV: Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 81:248–252, 1985 Reubi JC: Somatostatin analogue inhibits chondrosarcoma and insulinoma tumor growth. Acta Endocrinol 109:108–114, 1985 Richter G, Stockmann F, Lembcke B, Conlon JM, Creutzfeld W: Short-term administration of the somatostatin analogue SMS 201-995 in patients with carcinoid syndrome. Scand J Gastroenterol 21(suppl 119):193–198, 1986 Besser GM, Paxton AM, Johnson SAN, Moody EJ, Mortimer CH, Hall R, Gomez-Pan A, Schally AV, Kastin AJ, Coy DH: Impairment of platelet function of growth-hormone release-inhibiting hormone. Lancet 1:1166–1168, 1975 Krejs GJ, Orci LO, Conlon JM, Ravazzola M, Davis GR, Raskin P, Collins SM, McCarthy DM, Baetens D, Rubinstein A, Aldor TAM, Unger RH: Somatostatinoma syndrome: Biochemical, morphologic, and clinical features. N Engl J Med 301:285–292, 1979 O'Dorisio TM: Neuroendocrine disorders of the gastroenteropancreatic system. Am J Med 81(suppl 6B)54, 1986 (discussion) Wahren J, Eriksson LS: The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis. Scand J Gastroenterol 21(suppl 119):103–108, 1986